Key result
Conventional antipsychotics were associated with a 33% higher risk of all-cause mortality (HR 1.33) compared to atypical antipsychotics in elderly patients with cardiovascular or cerebrovascular disease.
Why the study?
Little is known about the comparative risk of death with atypical or conventional antipsychotics among persons with cardiovascular or cerebrovascular disease.
Does conventional antipsychotic use increase all-cause mortality compared to atypical antipsychotics in elderly persons with cardiovascular or cerebrovascular disease?
Cohort (n=51,762)
Yes
Does conventional antipsychotic use increase all-cause mortality compared to atypical antipsychotics in elderly persons with cardiovascular or cerebrovascular disease?
Hazard Ratio: 1.33 (95% CI 1.27–1.39)
Absolute Event Rate: 51.3% vs 38.5%
p-value: p=<0.001
In elderly patients with cardiovascular or cerebrovascular disease, conventional antipsychotics are associated with a significantly higher risk of all-cause mortality compared to atypical antipsychotics.
No takes yet. Share an insight, caveat, or question.
May support preferring atypicals in elderly CV patients; leaves open need for RCT confirmation.
Sultana et al. (2018) conducted a cohort in Cardiovascular or cerebrovascular disease (n=51,762). Conventional antipsychotics vs. Atypical antipsychotics was evaluated on All-cause mortality (HR 1.33, 95% CI 1.27-1.39, p=<0.001). Conventional antipsychotics were associated with a 33% higher risk of all-cause mortality (HR 1.33) compared to atypical antipsychotics in elderly patients with cardiovascular or cerebrovascular disease.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: